These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia. Herzig RH; Lazarus HM; Wolff SN; Phillips GL; Herzig GP J Clin Oncol; 1985 Jul; 3(7):992-7. PubMed ID: 3894588 [TBL] [Abstract][Full Text] [Related]
9. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Silverman LR; Holland JF; Weinberg RS; Alter BP; Davis RB; Ellison RR; Demakos EP; Cornell CJ; Carey RW; Schiffer C Leukemia; 1993 May; 7 Suppl 1():21-9. PubMed ID: 7683352 [TBL] [Abstract][Full Text] [Related]
11. [Treatment of myelodysplastic syndrome using continual subcutaneous infusion of low doses of cytosine arabinoside]. Vozobulová V; Koza V; Cepelák V; Neuwirtová R; Masek Z Vnitr Lek; 1990 May; 36(5):483-8. PubMed ID: 2375080 [TBL] [Abstract][Full Text] [Related]
12. Cytogenetic and clonal culture evaluation after response to low dose Ara-C in myelodysplastic syndromes. Hotta T; Goto S; Tsushita K; Kagami Y; Ohashi H; Ichikawa A; Ichihara M; Takagi N; Murate T; Yamao H Leukemia; 1991 Nov; 5(11):962-6. PubMed ID: 1961037 [TBL] [Abstract][Full Text] [Related]
13. 1,25-Dihydroxyvitamin D3: in vivo and in vitro effects on human preleukemic and leukemic cells. Koeffler HP; Hirji K; Itri L Cancer Treat Rep; 1985 Dec; 69(12):1399-407. PubMed ID: 2416438 [TBL] [Abstract][Full Text] [Related]
14. [High-dose cytosine arabinoside treatment of leukemia with special reference to the optimal number of doses]. Sampi K; Maseki N; Kumai R; Kaneko Y; Sakurai M; Hattori M Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 1):2595-8. PubMed ID: 2774589 [TBL] [Abstract][Full Text] [Related]
15. Chemotherapy for acute non-lymphocytic leukemia with low-dose cytosine arabinoside (Ara-C). Lin SF; Liu HW; Chen TP Nihon Ketsueki Gakkai Zasshi; 1990 Feb; 53(1):45-50. PubMed ID: 2330805 [TBL] [Abstract][Full Text] [Related]
16. [Value of high-dose cytosine-arabinoside in the treatment of resistant acute leukemia]. Witz F; Olive D; Lederlin P; Bordigoni P; Troussard X; Grosbois B; Schaison G; Cornu G Presse Med; 1987 Feb; 16(4):159-62. PubMed ID: 2950446 [TBL] [Abstract][Full Text] [Related]
17. Low-dose cytosine arabinoside regimen induced a complete remission with normal karyotypes in a case with hypoplastic acute myeloid leukaemia with No. 8-trisomy: in vitro and in vivo evidence for normal haematopoietic recovery. Tagawa M; Shibata J; Tomonaga M; Amenomori T; Yoshida Y; Kuriyama K; Matsuo T; Sadamori N; Ichimaru M Br J Haematol; 1985 Jul; 60(3):449-55. PubMed ID: 3860248 [TBL] [Abstract][Full Text] [Related]
18. Low-dose cytosine arabinoside in the treatment of acute nonlymphoblastic leukemia and myelodysplastic syndromes. Hoelzer D; Ganser A; Schneider W; Heimpel H Semin Oncol; 1985 Jun; 12(2 Suppl 3):208-11. PubMed ID: 4012339 [No Abstract] [Full Text] [Related]
19. A phase I study of intermittent continuous infusion high dose cytosine arabinoside for acute leukemia. Stone RM; Spriggs DR; Dhawan RK; Arthur KA; Mayer RJ; Kufe DW Leukemia; 1990 Dec; 4(12):843-7. PubMed ID: 2243507 [TBL] [Abstract][Full Text] [Related]
20. Post-remission therapy of adult acute myeloid leukemia: high dose cytosine-arabinoside versus other consolidation regimens. Zeremski V; Savić A Med Pregl; 2014; 67(3-4):83-90. PubMed ID: 24961049 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]